Compare Rambus Inc. Common Stock (RMBS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rambus Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Rambus Inc. Common Stock trades at $89.02 (market cap $9.99B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.50B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while Rambus Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rambus Inc. Common Stock for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| RMBS | ZBH | |
|---|---|---|
Market Cap | $9.99B | $17.50B |
Volume | 1,884,427 | 1,890,029 |
Sector | Technology | Health |
52-Week High | $170.66 | $103.98 |
52-Week Low | $79.73 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $9.19B | $24.57B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Zimmer Biomet (ZBH) trades at $92.08, down 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 8.56%. A quarterly dividend of $0.24 was recently declared, payable in October 2026.
The investment outlook is cautiously optimistic, driven by earnings beats and analyst consensus pointing to upside. Key risks include rising debt levels and competitive pressures. The consensus price target of $103.11 suggests potential appreciation, but investors should weigh margin trends and macroeconomic factors affecting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
